FDA Grants Fast Track Designation For Prevail's Parkinson's Treatment

FDA Grants Fast Track Designation For Prevail's Parkinson's Treatment

Source: 
Yahoo/Benzinga
snippet: 

Prevail Therapeutics (NASDAQ: PRVL) shares are trading higher after the company received FDA fast track designation for PR001 for the treatment of Parkinson's disease patients with a GBA1 mutation.